Full-Time

Machine Learning Research Scientist

Foundation Models

Genesis Molecular AI

Genesis Molecular AI

51-200 employees

AI-driven drug discovery platform for pharma

No salary listed

Remote in USA + 2 more

More locations: San Mateo, CA, USA | New York, NY, USA

Hybrid

PhD

Category
AI & Machine Learning (1)
Required Skills
LLM
Neural Networks
PyTorch
Machine Learning
Biochemistry
Reinforcement Learning

Get referred to Genesis Molecular AI

See people who can refer or advise you

Requirements
  • A deep learning expert with a portfolio of novel research in one or more cutting-edge domains of generative or predictive modeling, such as diffusion, flow matching, reinforcement learning, foundation model architectures, and training methods.
  • An independent, first-principles thinker with ownership of research projects and the ability to complete them.
  • Strong coding ability and comfort working deeply in the engineering stack to build, debug, and ship models.
  • Willingness to learn in the emerging field at the intersection of artificial intelligence, physics, chemistry, and biology; prior biology or chemistry experience is not required.
  • Strong communication skills and the ability to work collaboratively in a mission-driven science and engineering environment.
Responsibilities
  • Lead transformative research projects from conception to implementation, tackling core challenges in generative modeling for molecular systems.
  • Design and develop novel models and algorithms based on literature in diffusion models, flow matching, reinforcement learning, large language models, and other advanced areas.
  • Execute experiments at scale using computational infrastructure to validate hypotheses and advance the state of the art.
  • Collaborate with a multidisciplinary team to translate research into impact on the drug discovery platform.
  • Publish research and represent Genesis at artificial intelligence and machine learning conferences and workshops.
  • Mentor and guide other researchers and engineers.
Desired Qualifications
  • PhD in machine learning, computer science, or other computational sciences, or equivalent research experience demonstrated by a strong publication record.
  • Hands-on experience with PyTorch, PyTorch Lightning, Ray Distributed Training, and PyTorch Geometric.
  • Experience with distributed training and inference of large models on graphics processing unit clusters.
  • Familiarity with molecular data, including proteins and small molecules, physics-informed machine learning, or three-dimensional point-cloud data.

Genesis Molecular AI uses artificial intelligence to speed up drug discovery for the pharmaceutical industry. It combines 3D spatial graph modeling and advanced molecular simulation to generate and evaluate potential drug candidates and to uncover novel protein targets. The platform translates complex molecular data into actionable candidates by representing molecules in 3D graphs and running simulations to predict how they bind to target proteins, helping partners identify promising therapies. The company differentiates itself by integrating 3D spatial graph modeling with detailed molecular simulations to explore untapped chemical space and novel targets, and by focusing on business-to-business partnerships with pharma and biotech companies. Its goal is to accelerate drug discovery for partners by delivering AI-generated candidates and enabling faster progression from target to therapy.

Company Size

51-200

Company Stage

Late Stage VC

Total Funding

$400.1M

Headquarters

Burlingame, California

Founded

2019

Get referred to Genesis Molecular AI

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • May 2026 Incyte expansion delivered $120 million upfront, including $40 million equity.
  • Incyte will share proprietary data and fund compute, improving Genesis model training.
  • Genesis claims Pearl outperformed all cofolding models on OpenBind in October 2025.

What critics are saying

  • Incyte owns exclusive commercialization rights, limiting Genesis’s downstream capture through 2026.
  • OpenAI, Recursion, and Schrödinger intensify AI-drug-discovery competition for talent and partners.
  • If Pearl and GEMS miss wet-lab success, Genesis becomes a services vendor.

What makes Genesis Molecular AI unique

  • GEMS combines foundation models, physical simulation, and proprietary experimental data.
  • Genesis secured Incyte’s exclusive 2025 and expanded 2026 collaboration rights.
  • Sergey Edunov joined in December 2025 to scale foundation-model leadership.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Unlimited Paid Time Off

Parental Leave

Disability Insurance

Life Insurance

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

3%
Business Wire
May 21st, 2026
Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery

Incyte and Genesis expand molecular AI collaboration to accelerate 
drug discovery

Business News Today
Dec 3rd, 2025
Can Genesis Molecular AI leap ahead in biotech with Meta's Llama leader now onboard?

Can Genesis Molecular AI leap ahead in biotech with Meta's Llama leader now onboard? Genesis Molecular AI hires Meta's Llama leader Sergey Edunov to lead foundation models. Discover how this move strengthens its AI drug discovery platform. Genesis Molecular AI, the foundation model-driven drug design firm formerly known as Genesis Therapeutics, has appointed Sergey Edunov as Senior Vice President of Foundation Models. The executive hire marks a strategic inflection point as the company prepares to scale its GEMS platform and unveil new generative model research at the NeurIPS 2025 conference. Sergey Edunov is best known for his leadership role in developing Meta Platforms' Llama 2 and Llama 3 large language models. He brings over two decades of software engineering and AI research experience, having previously served as Senior Director of AI Research in Meta's generative AI division. His arrival at Genesis Molecular AI signals the firm's ambition to compete at the highest levels of foundation model development applied to molecular design.

Latest Nigerian News
Aug 7th, 2025
Genesis Therapeutics raises $52M for AI drug discovery

Genesis Therapeutics has successfully raised a $52 million A round to advance its AI-focused drug discovery mission. The company employs a novel simulation approach and a cross-disciplinary team to efficiently explore the vast array of potential medicinal molecules.

Today Media
May 28th, 2025
Incyte aims to accelerate drug research with AI collaboration

Earlier this year, Incyte inked a deal with Genesis Therapeutics to use the biotech company's AI platform to develop small molecule medicines.

Fierce Biotech
Feb 20th, 2025
Incyte pens $885M biobucks AI pact to use Genesis' GEMS to develop new drugs

Incyte is sticking to its strategy this year of finding "early-stage, exotic stuff" - paying Genesis Therapeutics $30 million upfront to use the biotech's artificial intelligence platform to develop small molecule medicines against undisclosed targets.